Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as MZ1449348
MZE001 · 1 trial · 1 indication
Occurrence of adverse events, serious adverse events, adverse events of special interest
| Arm | Type | Description |
|---|---|---|
| MZE001 | EXPERIMENTAL | MZE001 is a small molecule inhibitor of muscle glycogen synthase for the potential treatment of Pompe disease. |
| Placebo | PLACEBO_COMPARATOR | Excipients containing no active ingredients. |
| Name | Type | Description |
|---|---|---|
| MZE001 | DRUG | Small molecule inhibitor of muscle glycogen synthase |
| Placebo | DRUG | Product containing excipients with no active ingredients |
Inclusion Criteria: 1. Male and female subjects, ages 18 - 55 years, inclusive; 2. Must provide written informed consent prior to any study assessments and be willing and able to comply with all study procedures; 3. Body mass index (BMI) between 18.0 and 32.0 kg/m2 inclusive; 4. Healthy as determin...
MZE001 is an investigational small molecule developed by Maze Therapeutics, Inc. It is a Phase 1 clinical-stage candidate and has completed one randomized, placebo-controlled trial in healthy volunteers. It has not been approved by the FDA and remains in clinical development.
MZE001 targets GYS1, an enzyme. By acting on GYS1, the small molecule is designed to modulate the enzyme's activity. GYS1 is the only molecular target identified for MZE001 in its development program.
MZE001 is being developed by Maze Therapeutics, Inc., which trades under the ticker MAZE. The company is the sponsor of the drug's clinical program.
MZE001 is in Phase 1 clinical development. It is investigational and has not been approved by the FDA. One Phase 1 trial has been completed, and no active trials are currently listed for the program.
MZE001 has been studied in one completed Phase 1 trial, NCT05249621, titled a randomized Phase 1 of MZE001 in healthy volunteers. The trial enrolled 121 participants in the United States, was randomized, double-blind, and placebo-controlled, and included adults 18 years and older.